Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million

Financial Performance - Abeona Therapeutics Inc. closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million on June 27, 2025, contributing to a total cash resource of approximately $225 million as of June 30, 2025 [1][2] - The proceeds from the PRV, combined with existing cash, provide the company with over two years of operating capital, ensuring financial flexibility without the need for further capital infusion [2] Product Development - ZEVASKYN™ (prademagene zamikeracel) is the first and only U.S. approved autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [2][3] - The company anticipates the first patient treatment with ZEVASKYN in Q3 2025, with profitability projected for early 2026 [2] Company Overview - Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases [3] - The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio, which serves as the production site for ZEVASKYN [3]